Showing results (21-30 of 85) with videos related to
Sort By:
Pageof 9
British Journal of Haematology|October 15, 2016
Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab eraRobert Kridel, David Telio, Diego Villa, et al.Blood Advances|October 31, 2025
Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell LymphomaJean-Nicolas Champagne, Diego Villa, Alina S Gerrie, et al.British Journal of Haematology|April 10, 2015
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British ColumbiaKatharine H Xing, Amrit Kahlon, Brian F Skinnider, et al.Haematologica|March 5, 2026
Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVDJiayu Yang, Diego Villa, Alina S Gerrie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern eraAlden A Moccia, Jane Donaldson, Mukesh Chhanabhai, et al.British Journal of Haematology|October 22, 2016
Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experienceGreg Hapgood, Tom Pickles, Laurie H Sehn, et al.Blood Advances|December 6, 2019
Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarrayDiego Villa, King L Tan, Christian Steidl, et al.Leukemia & Lymphoma|June 28, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphomaAlden A Moccia, Felicitas Hitz, Paul Hoskins, et al.British Journal of Haematology|February 19, 2020
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorderMichael D Jain, Ryan Lam, Zhihui Liu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British ColumbiaGreg Hapgood, Yvonne Zheng, Laurie H Sehn, et al.Pageof 9